Publication Type | Academic Article |
Authors | Kim S, Kim E, Moon H, Yoon J, Koo J, Kim S, Kim M |
Journal | Magn Reson Imaging |
Volume | 54 |
Pagination | 176-182 |
Date Published | 08/30/2018 |
ISSN | 1873-5894 |
Keywords | Breast Neoplasms, Carcinoma, Ductal, Breast, Diffusion Magnetic Resonance Imaging, Receptor, ErbB-2, Receptors, Estrogen |
Abstract | PURPOSE: To determine whether T2 signal intensity, necrosis, and ADC values are associated with Ki-67 in patients with Estrogen Receptor (ER)-positive and Human epidermal growth factor receptor type 2 (HER2)-negative invasive ductal carcinoma (IDC). MATERIALS AND METHODS: Between March 2012 and February 2013, one hundred eighty seven women with ER-positive and HER2-negative IDC who underwent breast MRI and subsequent surgery were included. Intratumoral signal intensity was evaluated based on a combination of T2-weighted (low or equal, high, or very high) and contrast-enhanced MR images (enhancement or not). Necrosis was defined as very high T2 and no enhancement. Using the analysis of variance and pairwise t-test, a model based on intratumoral signal intensity was developed to assess Ki-67 of the surgical specimen. Inter-observer agreement for the developed model was analyzed. Conventional mean and minimum apparent diffusion coefficient (ADC) measurements were performed and correlated with Ki-67. RESULTS: As the grade of the developed model increased (Grade I: low or equal T2, Grade II: high T2, or necrosis < 50%, Grade III: necrosis ≥ 50%), mean Ki-67 significantly increased (Grade I to III: 12.5%, 17.6%, 45.0%, respectively; P < 0.001). Good inter-observer agreement was found for the model (κ = 0.846, P < 0.001). ADC did not show significant correlations with Ki-67 (Pearson's correlation coefficient, 0.140 [P = 0.057] for mean ADC; -0.079 [P = 0.284] for minimum ADC). CONCLUSION: Intratumoral signal intensity but not ADC was associated with Ki-67 in patients with ER-positive and HER2-negative IDC. |
DOI | 10.1016/j.mri.2018.08.017 |
PubMed ID | 30172938 |
PubMed Central ID | PMC7383359 |